Your browser doesn't support javascript.
loading
A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors.
Gouda, M A; Shunyakova, J; Naing, A; Dumbrava, E; Hong, D S; Yuan, Y; Yang, P; Myers, A; Liang, Y; Peng, J; Karp, D; Tsimberidou, A M; Rodon, J; Yap, T A; Piha-Paul, S A; Meric-Bernstam, F; Fu, S.
Afiliación
  • Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Shunyakova J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Dumbrava E; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Yuan Y; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.
  • Yang P; Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston.
  • Myers A; Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, USA.
  • Liang Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Peng J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Karp D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston.
  • Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston. Electronic address: siqingfu@mdanderson.org.
ESMO Open ; 9(6): 103486, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38914452
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Neoplasias Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: ESMO Open Año: 2024 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Paclitaxel / Neoplasias Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: ESMO Open Año: 2024 Tipo del documento: Article